Axial Therapeutics is a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological disorders and conditions.

The company is a scientific leader in the biological role of the microbiome-gut-brain axis and its influence on the central nervous system. Harnessing its unique expertise in the microbiome, Axial is developing small molecule drugs with defined mechanisms of action that act on new targets to mitigate the impact of metabolites and bacteria in the gut linked to neurological disorders and disease pathology, progression, and symptoms.

The company is advancing a pipeline of “microbial-inspired therapeutics™” for conditions with significant unmet patient need, including autism and Parkinson’s disease, and is also pursuing pre-clinical discovery of gut-targeted therapies in oncology.

Axial’s lead product candidate is AB-2004, a molecular therapeutic in Phase 2b clinical trials for the treatment of irritability in children with autism.

For more information, visit https://axialtx.com.

Our Mission

At Axial, our mission is to discover and develop targeted small molecule therapeutics to treat serious diseases and conditions by leveraging the microbiome’s role in human health. Our scientific focus on the microbiome gut-brain axis represents a transformative therapeutic approach that has potential to treat neurological diseases and disorders in ways never before possible.